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Abstract
The 2020 COVID-19 pandemic undermines the world economy, the affordability and accessibility of our
health systems. It puts an increasing strain on global production, supply and value chains. The research and
development of a set of COVID-19 vaccines is an unprecedented triumph of rapid innovation. The sense of
urgency has prompted academic research institutions, big pharmaceuticals and dedicated biotechnology
companies to develop vaccines targeting the SARS-CoV-2 coronavirus disease. Simultaneously, it unlocks
new value for business, patients and society. Consequently, new business models have come to the forefront.
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1 Context
Already in 1995, Laurie Garrett made a case for “newly emerging diseases in a world out of
balance”, expressing concern about the appearance of new infectious diseases. In 2015, Bill Gates
(gatesfoundation.org) launched a global warning on future disease epidemics, stating that “the
world needs to prepare for the next major health crisis”.
Since March 2020, the outbreak of the Wuhan Coronavirus disease (SARS-CoV-2) and the
COVID-19 pandemic has transformed the world as we know it, disrupting the business models of
civil society, (higher) education, world economy, business, governments, policies. We are witnesses
of a paradigm shift. It is up to us whether we will influence it or simply allow it to happen. Not
only in science-knowledge but also in human interactions and behaviour, basically all aspects of
our up-to-now comfortable life.
The 2020 COVID-19 pandemic undermines the world economy and has had an unprecedented
impact on health systems around the world. It is recalibrating businesses across sectors, not in
the least in healthcare and the biopharmaceutical industry. It unlocks new value for business,
customers and society.
The race to find both medicines and vaccines is reshaping the way companies – large and
small – collaborate and innovate in life saving projects while maintaining the drive of competition
in the long run. It triggered an unprecedented and intense level of global R&D activity and
collaboration by research teams in companies and universities across the world. Together with




university research centers and clinical research organizations, the biopharmaceutical companies
are actively involved in large-scale clinical and diagnostic testing and development of vaccines,
medicines, testing kits and near-patient testing devices. Manufacturing companies outside of
the life sciences industry (i.e. pharmaceuticals, biotechnology, medical devices,. . . ) are forming
partnerships with others to transform some of their manufacturing capacity to assemble much
needed critical equipment like ventilators and respiratory appliances (Chesbrough, 2020).
2 Time To Vaccine
The first and most important task today is to defeat the invisible enemy - the virus. Leading
pharmaceutical and dedicated biotechnology companies, academic institutions, governments and
the broader international scientific community are working together in public private partnerships
like never before to produce a treatment and speed up the time to vaccine.
Pharma and biotech companies within many cross-sector collaborations have taken the race
to the limit to develop a coronavirus vaccine, simultaneously waking the general public up to an
important warning sign: the time of going from concept to marketable product. The pharmaceutical
industry hoped to compress the time to market distribution to within 2021 at the earliest, being
significantly sooner than the 10 to 15 years the process of getting a new vaccine to market typically
takes.
3 Surfacing Business Models - The Biomolecular Platform Business Model
COVID-19 is transforming old and creating new business models of both cooperation, competition
and elements of open innovation. Coopetition describes a the phenomenon where companies both
compete and cooperate in a so-called cooperative competition. The following two “COVID-19
induced” business models have proven to be the most important since the outbreak of the
coronavirus disease.
Biomedical platforms have yielded new treatments – spanning various DNA-, RNA- and
cell-based therapies – with broad potential applications (Leclerc and Smith, 2018). Digital health
is a key part of the genetic information-driven business model of biomolecular platform companies.
The viability of a biomolecular platform as a therapeutic modality itself is the source of value
creation, e.g. whether the platform can be used to deliver vaccines. This approach is being applied
across a range of biomolecular platforms, from DNA-based gene therapies to CAR-T therapies to
emerging microbiome platforms. mRNA has only recently come into the focus as a potentially
powerful drug class able to deliver genetic information and to develop vaccines against infectious
diseases (Sahin, U., Karikó, K., Türeci, Ö, 2014), such as the coronavirus disease (COVID-19).
Currently, we are witnessing the successful widespread rollout of the Pfizer-BioNTech and Mod-
erna vaccines, next to the Janssen (Johnson & Johnson) and the more troublesome AstraZeneca
vaccine. GSK - the leading manufacturer of vaccines globally - partnered up with Sanofi. In the
partnership, Sanofi provides its recombinant antigen and GSK contributes its pandemic adjuvant.
GSK is also working together with CureVac for next generation mRNA vaccines.
3.2 The Public Private Partnership Business Model
Government funding and financing of translational research performed at universities and
research powerhouses have become increasingly important for the development of new vaccines.
This created a new momentum for the public private partnership business model, which is
increasingly deployed for the financing of clinical studies and to speed up production capacity





Source: Leclerc and Smith (2018) – McKinsey
Figure 1. Genetic-information-driven technologies
and societal impact – speeding up the worldwide available supply of vaccines and equitable access
of COVID-19 solutions. The private part (business side) relates to economic and regulatory issues,
investor financial returns and value co-creation.
In a first wave of research and development, leading (bio)pharmaceutical companies and
governments are working together in public private partnerships (PPP) like never before to produce
life-saving coronavirus vaccines (Segers and Gaile-Sarkane, 2020). According to Thanh Le et al.
(2020), it will be important to ensure coordination of vaccine manufacturing and supply capability
and capacity to meet demand. Pfizer-BioNTech, Moderna Therapeutics, Janssen (Johnson &
Johnson) and the alliance of Oxford University Hospitals, Oxford Biomedica and AstraZeneca have
made tremendous progress since the outbreak of the pandemic (see World Health Organization,
2021 (who.int)1).
In the second wave, the focus has shifted from speedy research and development of new vaccines
to leveraging the global production capacity. Companies are increasingly sharing infrastructure
and investing in leveraging joint production capacity.
A growing number of global Public Private Partnerships have been deployed to tackle the
COVID-19 crisis. They are explained in short below:
1. CEPI, the Coalition for Epidemic Preparedness Innovations, unites the network of governments,
pharmaceutical industry, regulators, academia, philanthropies, civil society and health organiza-
tions into a global health ecosystem (Debruyne, 2021). It is dedicated to finance independent
research projects to develop vaccines against emerging infectious diseases;
2. CEPI, GAVI (Global Vaccine Alliance) and the World Health Organization are co-leading
COVAX (COVID-19 Vaccines Global Access) to ensure equitable access to the vaccines.
COVAX is the vaccines pillar of the ACT-Accelerator; the ACT Accelerator (Access to COVID-
19 Tools) is a ground-breaking global collaboration to accelerate the development, production,






Source: Thanh Le et al. (2020)
Figure 2. Profile of COVID-19 vaccine developers
3. The Innovative Medicines Initiative (IMI) is the world’s biggest public-private partnership
in the life sciences. It is a joint technology initiative between the European Union and the
European Federation of Pharmaceutical Industries and Associations (EFPIA). The key goal
of IMI is speeding up the development of innovative medicines. The focus is currently on
the development of and access to therapeutics and diagnostics to tackle current and future
coronavirus outbreaks (drug development and repurposing);
4. HERA-Incubator - the European bio-defence preparedness plan – is a public private partnership
similar to BARDA (US Biomedical Advanced Research and Development Authority);
5. Operation Warp Speed in the United States, a national program with BARDA to accelerate
the development, manufacturing, and distribution of COVID-19 vaccines, therapeutics, and
diagnostics;
6. COVID-19 Technology Access Pool (C-TAP) is a call to action to voluntarily share knowledge,
intellectual property and data;
7. The Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) partnership,
i.e. a public-private partnership to speed COVID-19 vaccine and treatment options by the
National Institutes of Health in the United States. It brings together more than a dozen
leading biopharmaceutical companies, the FDA (Food and Drug Administration) and the EMA
(European Medicines Agency) to develop an international strategy for a coordinated research
response to the COVID-19 pandemic;
8. Open government approaches to tackling COVID-19 (Mention, 2020), building trust between
government and citizens, digital platforms or apps.
The pandemic is stimulating innovation in regulatory and IPR (intellectual property rights) issues
(Chesbrough, 2020). A number of countries and international organizations argue for removing IP
protections (open IP) on COVID-19 vaccines, medical tools and technologies during the duration of
the pandemic. They support a temporary global waiver of the Trade Related Intellectual Property
Rights (TRIPs – World Trade Organization) agreement. The TRIPs agreement introduced global
minimum standards for protecting and enforcing nearly all forms of intellectual property rights,
including those for patents. Scaling up mass vaccine and therapeutic production at lower prices is
key to achieving vaccine equity for developing countries, for global health security and preparedness
for future pandemics.





international collaboration between governments, private sector and other stakeholders, stating that
“IPRs are crucial to sustainable vaccine manufacturing scale-up and that an IP waiver would have
no effect on vaccine production without forced tech transfer, which would be extremely slow, beset
by legal difficulties and economically damaging”. Others argue that rapidly scaling of production of
vaccines implies enforced licensing deals with big pharma. According to Vanhaverbeke (2021), the
focus of governments should switch from waiving patent protection to different types of licensing
agreements with other pharma companies and generic drugmakers.
4 Exemplary Country Case: Belgium
The biopharmaceutical industry within biotech clusters around the world are more than ever
considered as strategic industries in many countries. The vibrant biotechnology and pharmaceutical
industry is one of the driving forces of the Belgian economy. According to the OECD reports,
Belgium is among the leading countries for performance in innovation and industry development
as measured by R&D-intensity, patent applications, the number of drugs in the pipeline, venture
capital invested in biotechnology and the number of new biotechnology firms.
The Belgian pharmaceutical industry is highly R&D-intensive, which explains the bioRegions
of Flanders and Wallonia hosting a number of global players in medical research and development
(Segers, 2017a; 2017b). Belgium plays a central role in the European Union for clinical trials and
translational vaccines research and production, given the historical presence of global pharmaceutical
companies and headquarters such as Pfizer, Janssen Pharmaceuticals (Johnson & Johnson) research
campus including JLABS, GlaxoSmithKline (GSK), Sanofi and many others. In addition, dedicated
new biotechnology firms like Ziphius Therapeutics – together with Univercells/Exothera/Quantoom
Biosciences – and eTheRNA are investing heavily in mRNA-based immunotherapies to create the
next generation of vaccines.
The Belgian biopharmaceutical industry rises to the occasion in three key areas: research
& development, manufacturing & production and logistics & distribution. In the combined
regional ecosystems of both Flanders and Wallonia (Segers, 2017a), the interplay between various
players and stakeholders (governments – high technology industries and industry-specific umbrella
organizations – academia and research institutions) provide a momentum towards the urgently
needed efficacious vaccines to contain the ongoing coronavirus disease. The ecosystems cover
every aspect of the biopharmaceutical value chain (Pharma.be, 2020):
• research and development and clinical trials;
• production (intermediary products, active pharmaceutical ingredients, raw materials, diagnostic
tools);
• a global logistics hub for medicines and vaccines and exports.
5 Conclusion
The COVID-19 pandemic undermines the world economy and our health systems. The joint battle
against the coronavirus led by governments and the global biopharmaceutical industry creates
new business models, leverages public private partnerships and enhances voluntary collaboration
between firms. The emergence of new platforms, treatments and therapies has been accompanied
by massive public and private investments in the search for efficacious COVID-19 vaccines. The
sense of urgency was translated in an unprecedented level of global R&D activity, collaboration by
research teams in companies and academia across the world. Questions and concerns remain with





ongoing discussion about intellectual property rights and patents. Take it to the limit !
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